Type 2 Diabetes Global Market Report 2024

Description

“Type 2 Diabetes Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on type 2 diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for type 2 diabetes? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The type 2 diabetes market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists; Thiazolidinediones; Alpha-Glucosidase Inhibitors; Sulfonylureas And Other Insulin Secretagogues; Biguanides; SodiumGlucose Cotransporter 2 Inhibitors; Other Drug Classes
2) By Application: Glycemic Control; Cardiovascular Safety; Hypoglycemia Avoidance; Other Applications
3) By End-User: Children; Adults
Companies Mentioned: F. Hoffmann-La Roche AG; Merck and Co. Inc; Novartis AG; AstraZeneca plc; Abbott Laboratories
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Type 2 diabetes is a persistent metabolic disorder characterized by elevated blood sugar levels attributed to insulin resistance and insufficient insulin production. The development of Type 2 diabetes is the result of a combination of genetic, lifestyle, and environmental factors. Effective management of type 2 diabetes can be achieved through dietary modifications, pharmaceutical interventions that aid in weight reduction, adherence to a healthy diet, and consistent physical activity.

In the realm of type 2 diabetes management, various classes of drugs are available, including dipeptidyl peptide-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas, other insulin secretagogues, biguanides, sodium-glucose cotransporter 2 inhibitors, and others. Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a class of oral medications designed to impede the action of the enzyme responsible for breaking down incretin hormones, which play a crucial role in regulating blood sugar levels. These drugs find applications in diverse areas, including glycemic control, cardiovascular safety, prevention of hypoglycemia, and more, catering to various age groups, including children and adults.

The type 2 diabetes market research report is one of a series of new reports from The Business Research Company that provides type 2 diabetes market statistics, including type 2 diabetes industry global market size, regional shares, competitors with a type 2 diabetes market share, detailed type 2 diabetes market segments, market trends and opportunities and any further data you may need to thrive in the type 2 diabetes industry. This type 2 diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The type 2 diabetes market size has grown strongly in recent years. It will grow from $44.56 billion in 2023 to $48.14 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to lifestyle and dietary changes, aging population, pharmaceutical developments, public health initiatives.

The type 2 diabetes market size is expected to see strong growth in the next few years. It will grow to $65.89 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to global diabetes epidemic, personalized medicine, technological advancements, healthcare policy changes. Major trends in the forecast period include digital health and telemedicine, prevention and early intervention, artificial intelligence (AI) and machine learning (ML), metabolic surgery.

The anticipated growth of the type 2 diabetes market is attributed to the escalating rates of obesity and heart disease. Obesity is a medical condition characterized by the accumulation of excess body fat to unhealthy levels, while heart disease encompasses a range of conditions affecting the heart and blood vessels. Excess body weight elevates the risk of insulin resistance, resulting in high blood sugar levels and the onset of type 2 diabetes. Conversely, elevated blood sugar levels can lead to the impairment of blood vessels and nerves that regulate heart and vascular functions, ultimately causing heart disease. For example, in May 2022, the Centers for Disease Control and Prevention, a US-based government agency, reported that severe obesity in the US surged from 4.7% to 9.2% in 2021. Moreover, a March 2022 report from the UK's Office for National Statistics, a government department, indicated an increase in the number of deaths from heart disease, rising from 19,440 in 2020 to 20,061 in 2021. Thus, the increasing prevalence of obesity and heart disease is the driving force behind the growth of the type 2 diabetes market.

The growth of the type 2 diabetes market is further fueled by the increasing geriatric population. This demographic comprises older adults aged 65 and above, who are more susceptible to various health conditions due to their lowered immunity and advanced age. Aging significantly heightens the risk of problems associated with Type 2 diabetes, including issues like hypoglycemia (low blood sugar), renal failure, and heart disease, impacting both acute and chronic microvascular and cardiovascular complications. As an illustration, a factsheet published by the World Health Organization in October 2021 highlighted that the global population aged 60 and over is projected to reach 1.4 billion by 2030, with a further increase to 2.1 billion by 2050. Hence, the growing geriatric population serves as a driving factor for the type 2 diabetes market.

The growth of the type 2 diabetes market is hampered by the increasing cost of medications during the forecast period. The high expenses associated with diabetes medications create financial barriers for individuals dealing with Type 2 Diabetes, especially those lacking sufficient insurance coverage or facing substantial out-of-pocket costs. This can result in delayed or inadequate treatment, leading to poorly controlled blood sugar levels and heightened health risks. For instance, in June 2021, as reported by the National Library of Medicine, a US-based medical library, the average lifetime cost for all medications employed in diabetes treatment is estimated at $23,380.17. On average, the total monthly cost per patient stands at $1,521, with $11.94 allocated to medical expenses and $3.26 to non-medical expenditures. Consequently, the soaring medication costs are a hindrance to the growth of the type 2 diabetes market.

Prominent companies operating in the type 2 diabetes market are pioneering innovative products such as Mounjaro to elevate the standards of safety and effectiveness in diabetic patient care. Innovative medications like Mounjaro aim to enhance the efficiency, safety, or convenience of diabetes management when compared to existing drugs. Advancements in the development of diabetes treatments focus on optimizing blood sugar regulation, minimizing adverse effects, and addressing other associated health issues. For instance, in May 2022, Eli Lilly and Co., a US-based pharmaceutical firm, secured approval from the U.S. Food and Drug Administration, a US-based government body, for Mounjaro (tripeptide) injection as an adjunct to diet and exercise for improving blood sugar control in adults with type 2 diabetes. Tirzepatide, a novel, dual-targeted therapy for type 2 diabetes, is delivered as a once-weekly injection, simultaneously targeting two hormones involved in blood sugar regulation, namely glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 contributes to increased insulin production and reduced glucagon production, while GIP stimulates insulin production. Tirzepatide stands as a promising novel treatment option for individuals with type 2 diabetes, including those who have responded poorly to other treatments.

In July 2021, Eli Lilly and Company, a US-based pharmaceutical enterprise, completed the acquisition of Protomer Technologies Inc. for $1 billion. Through this acquisition, Eli Lilly aims to bolster its diabetes pipeline by integrating Protomer's glucose-sensing insulin program. This strategic move accelerates the development of innovative treatments for individuals grappling with this chronic condition, providing a more precise and effective treatment option for diabetes patients. Protomer Technologies Inc., based in the US, is a biotechnology company known for its development of PT-100, a small molecule intended for the treatment of type 2 diabetes.

Major players in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Novartis AG, AstraZeneca PLC, Abbott Laboratories, Sanofi SA, Medtronic PLC, Takeda Pharmaceutical Company, GlaxoSmithKline plc., Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Dexcom Inc., Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Byram Healthcare, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health .

North America was the largest region in the type 2 diabetes market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in type 2 diabetes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the type 2 diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The type 2 diabetes market consists of revenues earned by entities by providing services such as blood sugar monitoring, diabetes education and support, bariatric surgery and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The type 2 diabetes market also includes sales of blood glucose meters, insulin pens, insulin syringes, insulin pumps, metformin and diabetic socks. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12396

1. Executive Summary

2. Type 2 Diabetes Market Characteristics

3. Type 2 Diabetes Market Trends And Strategies

4. Type 2 Diabetes Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Type 2 Diabetes Market Size and Growth

5.1. Global Type 2 Diabetes Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Type 2 Diabetes Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Type 2 Diabetes Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Type 2 Diabetes Market Segmentation

6.1. Global Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Thiazolidinediones
Alpha-Glucosidase Inhibitors
Sulfonylureas And Other Insulin Secretagogues
Biguanides
SodiumGlucose Cotransporter 2 Inhibitors
Other Drug Classes
6.2. Global Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Glycemic Control
Cardiovascular Safety
Hypoglycemia Avoidance
Other Applications
6.3. Global Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Children
Adults

7. Type 2 Diabetes Market Regional And Country Analysis

7.1. Global Type 2 Diabetes Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Type 2 Diabetes Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Type 2 Diabetes Market

8.1. Asia-Pacific Type 2 Diabetes Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Type 2 Diabetes Market

9.1. China Type 2 Diabetes Market Overview
9.2. China Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Type 2 Diabetes Market

10.1. India Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Type 2 Diabetes Market

11.1. Japan Type 2 Diabetes Market Overview
11.2. Japan Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Type 2 Diabetes Market

12.1. Australia Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Type 2 Diabetes Market

13.1. Indonesia Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Type 2 Diabetes Market

14.1. South Korea Type 2 Diabetes Market Overview
14.2. South Korea Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Type 2 Diabetes Market

15.1. Western Europe Type 2 Diabetes Market Overview
15.2. Western Europe Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Type 2 Diabetes Market

16.1. UK Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Type 2 Diabetes Market

17.1. Germany Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Type 2 Diabetes Market

18.1. France Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Type 2 Diabetes Market

19.1. Italy Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Type 2 Diabetes Market

20.1. Spain Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Type 2 Diabetes Market

21.1. Eastern Europe Type 2 Diabetes Market Overview
21.2. Eastern Europe Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Type 2 Diabetes Market

22.1. Russia Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Type 2 Diabetes Market

23.1. North America Type 2 Diabetes Market Overview
23.2. North America Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Type 2 Diabetes Market

24.1. USA Type 2 Diabetes Market Overview
24.2. USA Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Type 2 Diabetes Market

25.1. Canada Type 2 Diabetes Market Overview
25.2. Canada Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Type 2 Diabetes Market

26.1. South America Type 2 Diabetes Market Overview
26.2. South America Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Type 2 Diabetes Market

27.1. Brazil Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Type 2 Diabetes Market

28.1. Middle East Type 2 Diabetes Market Overview
28.2. Middle East Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Type 2 Diabetes Market

29.1. Africa Type 2 Diabetes Market Overview
29.2. Africa Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Type 2 Diabetes Market Competitive Landscape And Company Profiles

30.1. Type 2 Diabetes Market Competitive Landscape
30.2. Type 2 Diabetes Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Merck and Co. Inc
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Novartis AG
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AstraZeneca plc
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Abbott Laboratories
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Type 2 Diabetes Market Other Major And Innovative Companies

31.1. Sanofi SA
31.2. Medtronic plc
31.3. Takeda Pharmaceutical Company
31.4. GlaxoSmithKline plc.
31.5. Eli Lilly and Company
31.6. Novo Nordisk A/S
31.7. Johnson And Johnson Private Limited
31.8. Daiichi Sankyo Co. Ltd
31.9. Boehringer Ingelheim International GmbH
31.10. Dexcom Inc
31.11. Amgen Inc.
31.12. Insulet Corporation
31.13. Ascensia Diabetes Care
31.14. Byram Healthcare
31.15. Beta Bionics

32. Global Type 2 Diabetes Market Competitive Benchmarking

33. Global Type 2 Diabetes Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Type 2 Diabetes Market

35. Type 2 Diabetes Market Future Outlook and Potential Analysis

35.1 Type 2 Diabetes Market In 2028 - Countries Offering Most New Opportunities
35.2 Type 2 Diabetes Market In 2028 - Segments Offering Most New Opportunities
35.3 Type 2 Diabetes Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer